The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.
 
Eric Christenson
Consulting or Advisory Role - Seres Therapeutics
Research Funding - Haystack Oncology; Pfizer
Other Relationship - Natera
(OPTIONAL) Uncompensated Relationships - Brenus Pharma
 
Daruka Mahadevan
Honoraria - Caris Life Sciences; Guardant Health
Speakers' Bureau - Caris Life Sciences; Guardant Health
Travel, Accommodations, Expenses - Caris Life Sciences; Guardant Health
 
Syed Mohammad Ali Kazmi
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Sudhir Manda
No Relationships to Disclose
 
Davendra Sohal
Consulting or Advisory Role - AADi; AstraZeneca/MedImmune; Bayer; Elevar Therapeutics; Regeneron; Totus Medicines; TransThera Sciences (Nanjing), Inc.; Valar Labs
Speakers' Bureau - AstraZeneca; Incyte; Seagen
Research Funding - Ability Pharma (Inst); Amgen (Inst); Apexigen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bexion (Inst); Bristol-Myers Squibb (Inst); FibroGen (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); NextCure (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Triumvira Immunologics, Inc (Inst)
Travel, Accommodations, Expenses - Ability Pharma
 
Thomas E. Hutson
Employment - Texas Oncology
Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst)
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); CUE Biopharma (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); Pionyr (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)
 
Ashley Martz
Employment - NextCure
Stock and Other Ownership Interests - NextCure
 
Stephanie Kordahi
Employment - NextCure
Stock and Other Ownership Interests - NextCure
 
Emilia Alina Barbu
No Relationships to Disclose
 
Dallas Flies
Employment - NextCure
Stock and Other Ownership Interests - NextCure
Patents, Royalties, Other Intellectual Property - Patent for compositions and methods for modulating lair signal transduction
 
Solomon Langermann
Employment - NextCure
Stock and Other Ownership Interests - NextCure
 
Michael Jon Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Consulting or Advisory Role - Celularity; Guardant Health; Sanofi
Speakers' Bureau - BMS; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
Marc Ryan Matrana
Consulting or Advisory Role - AstraZeneca; Strata Oncology
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Eisai; Exelixis; Genentech; Janssen; Merck; Seagen
 
Alex Spira
No Relationships to Disclose
 
Raymond Couric Wadlow
Honoraria - AstraZeneca; Oncocyte; Pfizer; Seagen; Taiho Pharmaceutical
Consulting or Advisory Role - Exact Sciences; Johnson & Johnson (I)
Travel, Accommodations, Expenses - Exact Sciences
 
Udayan Guha
Employment - NextCure Inc.; TCR2 Therapeutics
Stock and Other Ownership Interests - NextCure; TCR2 Therapeutics
 
Han Myint
Employment - NextCure
Leadership - NextCure
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene; NextCure
 
Dung T. Le
Honoraria - Merck
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Catenon; G1 Therapeutics; HalioDX; Janssen; Merck; Merus NV; Nouscom; Regeneron; Tango Therapeutics; Taovtek Biotherapeutics
Research Funding - Abbvie (Inst); Aduro Biotech; Bristol-Myers Squibb; Curegenix; Medivir; Merck; Nouscom (Inst)
Patents, Royalties, Other Intellectual Property - Inventor of technology, "Microsatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition".